Moleculin Biotech, Inc.
Datakwaliteit: 100%
MBRX
Nasdaq
Manufacturing
Chemicals
€ 2,62
▲
€ 0,07
(2,75%)
Marktkapitalisatie: 13,55 M
Prijs
€ 2,54
Marktkapitalisatie
13,55 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—
Quick Summary
Belangrijkste Punten
Negative free cash flow of -22,74 M
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
N/A
ROIC-139,90%
Net MarginN/A
Op. MarginN/A
Veiligheid
Debt / Equity
N/A
Current Ratio1,39
Interest CoverageN/A
Waardering
PE (TTM)
-0,40
Boven sectorgemiddelde (-1,48)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -0,4 | -1,5 |
| P/B | — | 1,6 |
| ROE % | — | -53,4 |
| Net Margin % | — | -41,5 |
| Rev Growth 5Y % | — | 1,8 |
| D/E | — | 0,3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 0,0 | Net Income (TTM) | -33,56 M |
| ROE | N/A | ROA | -160,02% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -22,74 M |
| ROIC | -139,90% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 1,39 |
| Interest Coverage | N/A | Asset Turnover | 0,00 |
| Working Capital | 2,20 M | Tangible Book Value | -26,92 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -0,40 | Forward P/E | N/A |
| P/B Ratio | N/A | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -167,73% | ||
| Market Cap | 13,55 M | Enterprise Value | 6,85 M |
| Per Share | |||
| EPS (Diluted TTM) | N/A | Revenue / Share | 0,00 |
| FCF / Share | -4,26 | OCF / Share | -4,26 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 67,74% |
| SBC-Adj. FCF | -24,29 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 |
| Net Income | -33,56 M | -21,76 M | -29,77 M | -29,03 M | -15,89 M |
| EPS (Diluted) | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -25,10 M | -26,64 M | -29,63 M | -30,64 M | -22,97 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 15,89 M | 17,73 M | 19,49 M | 18,97 M | 14,42 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | 90.000,0 | 126.000,0 | 127.000,0 | 130.000,0 | 164.000,0 |
| Interest Expense | — | — | — | 240.000,0 | 306.000,0 |
| Income Tax | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 22,13 M | 16,93 M | 38,22 M | 57,42 M | 84,09 M |
| Total Liabilities | 7,12 M | 10,95 M | 12,14 M | 5,23 M | 5,10 M |
| Shareholders' Equity | 15,01 M | 5,98 M | 26,07 M | 52,19 M | 78,99 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 8,88 M | 4,28 M | 23,55 M | 43,15 M | 70,90 M |
| Current Assets | 9,69 M | 5,19 M | 26,27 M | 45,60 M | 72,50 M |
| Current Liabilities | 6,85 M | 5,36 M | 6,82 M | 4,82 M | 3,62 M |
{"event":"ticker_viewed","properties":{"ticker":"MBRX","listing_kind":"stock","pathname":"/stocks/mbrx","exchange":"Nasdaq","country":"US"}}